Ligand id: 6591

Name: natalizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: natalizumab

Compound class Antibody
Approved drug? Yes (FDA (2004), EMA (2006))
International Nonproprietary Names
INN number INN
7716 natalizumab
AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a significant new focus for the development of novel anti-inflammatory therapeutics [2].
The design and synthesis of this antibody is described in [1], but the article is not open access.
Database Links
Specialist databases
IMGT/mAb-DB 75
Other databases
GtoPdb PubChem SID 178103204
PubChem SID 178103204
Search PubMed clinical trials natalizumab
Search PubMed titles natalizumab
Search PubMed titles/abstracts natalizumab
Wikipedia Natalizumab